Home / Stocks / ELAN

Elanco Animal Health (ELAN, Drugmakers) Stock Valuation & Fair Value

Weak on forward returns

Elanco Animal Health (ELAN, Drugmakers) trades at a current P/E of 23.5, about 4% above its historical normal valuation, with a forward growth estimate of 12.6% and a PEG of 1.86. Analysts' one-year estimates have been hit 57% of the time. Priced at its historical normal P/E of 22.6 on the same blended earnings, the 2026-11-06 close of $25.74 corresponds to about $24.90 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
23.5
Normal P/E
22.6
PEG
1.86
Fwd growth
12.6%
Div yield
0.0%
RSI (14)
65.5
Neutral
Technical context
  • Price $25.74 at the Nov 6 close, 10.3% above the 20-day average ($23.33) and 11.3% above the 50-day ($23.13).
  • RSI (14) at 65.5.
  • 52-week range $19.80 to $26.84: the price is 4.1% below the high and 30.0% above the low.

The Street vs SeerForecast

Wall Street's mean price target for ELAN is $30.23 across 13 analysts, 17.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: weak on forward returns. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been weak on forward returns since 2026-07-31.

Current P/E and rating by weekCurrent P/E moved from 26.1 to 21.0 between 2026-07-31 and 2026-10-30, against a normal P/E of 22.6, with 0 rating changes over 14 recorded weeks.2026-07-31: P/E 26.1, Weak on forward returns, recalculated for the week of 2026-07-312026-07-31: P/E 26.0, Weak on forward returns, recorded live 2026-08-032026-08-07: P/E 26.0, Weak on forward returns, recalculated for the week of 2026-08-072026-08-07: P/E 21.1, Weak on forward returns, recorded live 2026-08-102026-08-14: P/E 21.1, Weak on forward returns, recalculated for the week of 2026-08-142026-08-14: P/E 22.5, Weak on forward returns, recorded live 2026-08-172026-08-21: P/E 22.5, Weak on forward returns, recalculated for the week of 2026-08-212026-08-21: P/E 22.6, Weak on forward returns, recorded live 2026-08-242026-08-27: P/E 22.6, Weak on forward returns, recalculated for the week of 2026-08-272026-08-28: P/E 22.6, Weak on forward returns, recalculated for the week of 2026-08-282026-08-28: P/E 22.6, Weak on forward returns, recalculated for the week of 2026-08-302026-08-28: P/E 22.6, Weak on forward returns, recorded live 2026-08-312026-09-04: P/E 22.6, Weak on forward returns, recalculated for the week of 2026-09-052026-09-04: P/E 22.9, Weak on forward returns, recorded live 2026-09-072026-09-11: P/E 22.9, Weak on forward returns, recalculated for the week of 2026-09-122026-09-11: P/E 21.6, Weak on forward returns, recorded live 2026-09-142026-09-18: P/E 21.6, Weak on forward returns, recalculated for the week of 2026-09-192026-09-18: P/E 20.8, Weak on forward returns, recorded live 2026-09-212026-09-25: P/E 20.8, Weak on forward returns, recalculated for the week of 2026-09-262026-09-25: P/E 20.7, Weak on forward returns, recorded live 2026-09-282026-10-02: P/E 20.7, Weak on forward returns, recalculated for the week of 2026-10-032026-10-02: P/E 20.4, Weak on forward returns, recorded live 2026-10-052026-10-09: P/E 20.4, Weak on forward returns, recalculated for the week of 2026-10-102026-10-09: P/E 21.1, Weak on forward returns, recorded live 2026-10-122026-10-16: P/E 21.1, Weak on forward returns, recalculated for the week of 2026-10-172026-10-16: P/E 21.6, Weak on forward returns, recorded live 2026-10-192026-10-23: P/E 20.6, Weak on forward returns, recorded live 2026-10-262026-10-30: P/E 20.6, Weak on forward returns, recalculated for the week of 2026-10-312026-10-30: P/E 21.0, Weak on forward returns, recorded live 2026-11-0222.024.026.0Jul 31Aug 23Sep 15Oct 7Oct 30Normal P/E 22.6
Weak on forward returns

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 26.1+15%Weak on forward returns (recalculated)
2026-10-05P/E 20.4-10%Weak on forward returns
2026-11-02P/E 21.0-7%Weak on forward returns ← now
Show all 29 readings
WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 26.1+15%Weak on forward returns (recalculated)
2026-08-03P/E 26.0+15%Weak on forward returns
2026-08-07P/E 26.0+15%Weak on forward returns (recalculated)
2026-08-10P/E 21.1-7%Weak on forward returns
2026-08-14P/E 21.1-7%Weak on forward returns (recalculated)
2026-08-17P/E 22.5-1%Weak on forward returns
2026-08-21P/E 22.5-1%Weak on forward returns (recalculated)
2026-08-24P/E 22.6-0%Weak on forward returns
2026-08-27P/E 22.6-0%Weak on forward returns (recalculated)
2026-08-28P/E 22.6-0%Weak on forward returns (recalculated)
2026-08-30P/E 22.6-0%Weak on forward returns (recalculated)
2026-08-31P/E 22.6-0%Weak on forward returns
2026-09-05P/E 22.6-0%Weak on forward returns (recalculated)
2026-09-07P/E 22.9+1%Weak on forward returns
2026-09-12P/E 22.9+1%Weak on forward returns (recalculated)
2026-09-14P/E 21.6-5%Weak on forward returns
2026-09-19P/E 21.6-5%Weak on forward returns (recalculated)
2026-09-21P/E 20.8-8%Weak on forward returns
2026-09-26P/E 20.8-8%Weak on forward returns (recalculated)
2026-09-28P/E 20.7-9%Weak on forward returns
2026-10-03P/E 20.7-9%Weak on forward returns (recalculated)
2026-10-05P/E 20.4-10%Weak on forward returns
2026-10-10P/E 20.4-10%Weak on forward returns (recalculated)
2026-10-12P/E 21.1-7%Weak on forward returns
2026-10-17P/E 21.1-7%Weak on forward returns (recalculated)
2026-10-19P/E 21.6-5%Weak on forward returns
2026-10-26P/E 20.6-9%Weak on forward returns
2026-10-31P/E 20.6-9%Weak on forward returns (recalculated)
2026-11-02P/E 21.0-7%Weak on forward returns ← now

Frequently asked questions

Is Elanco Animal Health stock overvalued?

At a current P/E of 23.5 versus its historical normal P/E of 22.6, Elanco Animal Health trades about 4% above its typical valuation, with a PEG of 1.86 on 12.6% forward growth. tickerseer currently rates it weak on forward returns.

What is Elanco Animal Health's fair value and PEG?

Elanco Animal Health trades at a current P/E of 23.5 against a historical normal P/E of 22.6, a PEG of 1.86, and a forward growth estimate of 12.6%. Priced at its historical normal P/E of 22.6 on the same blended earnings, the 2026-11-06 close of $25.74 corresponds to about $24.90 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Elanco Animal Health changed?

tickerseer's rating has been weak on forward returns since 2026-07-31.

What is the analyst price target for Elanco Animal Health?

The mean Wall Street price target for Elanco Animal Health is $30.23 across 13 analysts, 17.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Drugmakers. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ELAN free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.